Payment overview · 2025
General Payments
$839.83
35 reported records · 16 companies
Healthcare provider profile · identity verified
Keith A Bernstein, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · CHESTERFIELD, MO · NPI 1447273727
Verified facts
What the public records show
CMS Open Payments records show Keith A Bernstein, MD received $839.83 in general payments during 2025 across 35 reported records.
GlaxoSmithKline, LLC. accounted for 14.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Benlysta, Enbrel.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Enbrel by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Benlysta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $119.11 | 14.2% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $116.82 | 13.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $102.89 | 12.2% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$80.97 | 9.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $77.03 | 9.2% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $51.88 | 6.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.91 | 5.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40.25 | 4.8% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $36.06 | 4.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.13 | 3.8% | 2 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $30.46 | 3.6% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.88 | 3.3% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $25.73 | 3.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.14 | 2.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.44 | 2.2% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.13 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $839.83 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $116.82 | 4 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $80.97 | 1 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $75.43 | 4 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $66.76 | 3 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $52.71 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $51.88 | 3 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $43.68 | 2 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $42.91 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $40.25 | 2 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $36.06 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $30.46 | 1 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $27.88 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $25.73 | 1 | 2025 |
Source payment records
|
|||||
| ILARIS Normalized: ilaris |
Drug | Novartis Pharmaceuticals Corporation | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ENBREL enbrel |
2025 | Enbrel | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 481 | 131 |
| Methotrexate | Methotrexate Sodium | 321 | 86 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 206 | 49 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 195 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 177 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 172 | 43 |
| Lisinopril | Lisinopril | 148 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 104 | 20 |
| Meloxicam | Meloxicam | 103 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 100 | 27 |
| Losartan Potassium | Losartan Potassium | 99 | 26 |
| Alprazolam | Alprazolam | 96 | 26 |
| Gabapentin | Gabapentin | 96 | 33 |
| Omeprazole | Omeprazole | 81 | 22 |
| Sertraline Hcl | Sertraline Hcl | 77 | 18 |
| Eliquis | Apixaban | 76 | 15 |
| Leflunomide | Leflunomide | 72 | 16 |
| Furosemide | Furosemide | 63 | 16 |
| Trazodone Hcl | Trazodone Hcl | 63 | 18 |
| Tramadol Hcl | Tramadol Hcl | 62 | 13 |
| Celecoxib | Celecoxib | 60 | 15 |
| Allopurinol | Allopurinol | 59 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 14 |
| Folic Acid | Folic Acid | 53 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 53 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 48 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 11 |
| Azithromycin | Azithromycin | 44 | 36 |
| Simvastatin | Simvastatin | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 13 |
| Metformin Hcl | Metformin Hcl | 37 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 27 | 27 |
| Benlysta | Belimumab | 27 | suppressed |
| Humira(Cf) Pen | Adalimumab | 27 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Actemra | Tocilizumab | 25 | suppressed |
| Enbrel Sureclick | Etanercept | 25 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Enbrel | Etanercept | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Rasuvo | Methotrexate/Pf | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Indomethacin Er | Indomethacin | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $839.83 · 35 records | GlaxoSmithKline, LLC. | BENLYSTA, COSENTYX, Dexcom G6 Transmitter, ENBREL, FREESTYLE LIBRE 3, ILARIS, MINIMED 780G, NUCALA, OTEZLA, PURIFIED CORTROPHIN GEL, SAPHNELO, SKYRIZI, STRENSIQ, TALTZ, TREMFYA, TWIIST, Tymlos, UPLIZNA, Wegovy, XELJANZ | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Benlysta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error